{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:16Z","timestamp":1790368096634,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007525","name":"Universit\u00e9 de Rennes 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007525","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.pupt.2023.102267","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T11:41:53Z","timestamp":1700048513000},"page":"102267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7658-0695","authenticated-orcid":false,"given":"Audrey","family":"Joannes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudie","family":"Morzadec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Letellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Llamas","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Cristian","family":"Chiforeanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Le Naoures","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand Richard","family":"De Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Jaillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Wollin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Jouneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Vernhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2023.102267_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2023.102267_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2023.102267_bib3","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur. Respir. Rev. Off. J. Eur. Respir. Soc."},{"key":"10.1016\/j.pupt.2023.102267_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.799912","article-title":"The burden of progressive-fibrosing interstitial lung diseases","volume":"9","author":"Cottin","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.pupt.2023.102267_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01449-2022","article-title":"Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed)","volume":"60","author":"Cottin","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102267_bib6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pupt.2023.102267_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04507-2020","article-title":"When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases","author":"Selman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102267_bib8","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"INBUILD trial investigators, nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2023.102267_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"INBUILD trial investigators, Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2023.102267_bib10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102267_bib11","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1164\/rccm.200212-1514OC","article-title":"Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis","volume":"168","author":"Marchand-Adam","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102267_bib12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102267_bib13","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"American thoracic society, European respiratory society, Japanese respiratory society, and Latin American thoracic society, diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102267_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00408-004-2534-z","article-title":"Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts","volume":"183","author":"Hetzel","year":"2005","journal-title":"Lung"},{"key":"10.1016\/j.pupt.2023.102267_bib15","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.pupt.2023.102267_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1465-9921-7-95","article-title":"Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis","volume":"7","author":"Chilosi","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2023.102267_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"15","author":"Hostettler","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2023.102267_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel mechanisms for the antifibrotic action of nintedanib","volume":"54","author":"Rangarajan","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.pupt.2023.102267_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"Suppl 119","key":"10.1016\/j.pupt.2023.102267_bib20","first-page":"115","article-title":"Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease","volume":"37","author":"Atanelishvili","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.pupt.2023.102267_bib21","article-title":"Matrix stiffness regulates migration of human lung fibroblasts","volume":"5","author":"Asano","year":"2017","journal-title":"Phys. Rep."},{"key":"10.1016\/j.pupt.2023.102267_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12931-022-02116-4","article-title":"Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis","volume":"23","author":"Hesse","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2023.102267_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","article-title":"A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly","volume":"57","author":"Kn\u00fcppel","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.pupt.2023.102267_bib24","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.pupt.2023.102267_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.pupt.2023.102267_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102267_bib27","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur. Respir. Rev. Off. J. Eur. Respir. Soc."},{"key":"10.1016\/j.pupt.2023.102267_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41420-022-00831-x","article-title":"Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.pupt.2023.102267_bib29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3390\/cells11040664","article-title":"Comparative analysis of gene expression in fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis","volume":"11","author":"Kamp","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pupt.2023.102267_bib30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MCP.0000000000000907","article-title":"Pleuroparenchymal fibroelastosis","volume":"28","author":"Cottin","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.pupt.2023.102267_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s13023-021-02043-5","article-title":"Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis","volume":"16","author":"Nasser","year":"2021","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:32:50Z","timestamp":1761082370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":31,"alternative-id":["S1094553923000792"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102267","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102267"}}